Newsroom

Download PDF CAMBRIDGE, Mass., September 4, 2009 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Rodman & Renshaw 11th Annual Healthcare Conference on Friday, September 11, 2009 at 10:50 a.m. (EDT) at the New York Palace Hotel in New York City. About AVEO

Download PDF CAMBRIDGE, Mass., August 4, 2009 – AVEO Pharmaceuticals, Inc. today announced that Elan Ezickson, chief business officer, is scheduled to present at the Canaccord Adams 29th Annual Global Growth Conference on Tuesday, August 11, 2009 at 3:00 p.m. (EDT) at the InterContinental Hotel in Boston, Mass. About AVEO AVEO is a late-stage biopharmaceutical

Download PDF Preclinical Data Presented at International Lung Conference; Underscores Tivozanib Potency CAMBRIDGE, Mass., July 31, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced data which demonstrates that tivozanib (AV-951) – the company’s oral, triple VEGF receptor inhibitor –

Download PDF CAMBRIDGE, Mass., July 30, 2009 – AVEO Pharmaceuticals, Inc. today announced that Murray Robinson, Ph.D., senior vice president, oncology, is scheduled to present at IBC’s New Frontiers in Cancer Drug Development Conference on Tuesday, August 4, 2009 at 1:40 p.m. (EDT) at the World Trade Center Boston/Seaport Hotel in Boston, Mass. Dr. Robinson

Download PDF MELVILLE, NY and CAMBRIDGE, Mass., July 21, 2009 – OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) and AVEO Pharmaceuticals, Inc. today announced that they have expanded the drug discovery and translational research collaboration announced in October of 2007. The alliance is anchored around developing molecular targeted therapies to target the underlying mechanisms of epithelial-mesenchymal transition (EMT)

Download PDF Novel Technology Allows Rapid Production of Genetically Defined In Vivo Tumor Models CAMBRIDGE, Mass., July 8, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that the United States Patent and Trademark Office granted to AVEO U.S. Patent

Download PDF – Discovery of HeyL Gene Expression as Biomarker Marks Critical Step in Developing Targeted Therapeutics to Inhibit Notch Pathway – CAMBRIDGE, Mass., June 17, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that the United States Patent

Download PDF CAMBRIDGE, Mass., June 5, 2009 – AVEO Pharmaceuticals, Inc. today announced that Elan Ezickson, chief business officer, is scheduled to present at the 8th Annual Needham & Company Life Sciences Conference on Thursday, June 11, 2009 at 9:00 a.m. (EDT) at the New York Palace Hotel in New York City. About AVEO AVEO